Sep 29, 2022ML161 greatly improves kidney function in a mouse model of diabetic kidney diseaseDrs. Shrey Kohli, Berend Isermann, and team report in Nature Communications that the PAR1-targeting parmodulin ML161 (aka Parmodulin 2)...
Sep 13, 2022Paul Ornstein, Ph.D. joins as VP of Preclinical DevelopmentFunction Therapeutics is pleased to welcome Dr. Paul Ornstein as its VP of Preclinical Development. Paul trained with a series of...
Apr 15, 2022Function Therapeutics receives Dept. of Defense awardFunction Therapeutics, Inc. received official notice of a U.S. Department of Defense Peer Reviewed Medical Research Program Discovery...
